Bayer To Invest $150 Million for Cell Culture Technology Center
Bayer has announced that it will invest $150 million in its pharmaceutical development and manufacturing site in Berkeley, California to build a Cell Culture Technology Center that will be used to support Bayer’s portfolio of biologics.
The new Cell Culture Technology Center will be built on Bayer’s existing Berkeley campus, which has its recombinant Factor VIII manufacturing center that produces treatments for hemophilia A. The new 40,000-square-foot facility, which is expected to be ready for clinical production in late 2021, will support the development of emerging therapies in Bayer’s portfolio with an emphasis on oncology, cardiology and additional specialty-care therapeutic areas.
Bayer has selected Fluor for design and construction, and GE Healthcare for the integration of its FlexFactory technology platform into the center.
Two years ago, Bayer oriented its pharmaceutical strategy around key specialty care therapeutic areas and recently has increased its R&D focus on open innovation. The center is being designed to support candidates in its drug pipeline and enable development of new assets resulting from a range of collaborations coming from Bayer’s open innovation approach.
Bayer’s presence on the US West Coast includes a pharmaceutical development and manufacturing facility in Berkeley and the Innovation Center in San Francisco, which houses CoLaborator, an incubator for life-science start-ups.